

Benedicte Deau

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5969441/publications.pdf>

Version: 2024-02-01

14
papers

174
citations

1163117

8
h-index

1125743

13
g-index

14
all docs

14
docs citations

14
times ranked

392
citing authors

#	ARTICLE	IF	CITATIONS
1	Consolidation anti-CD22 fractionated radioimmunotherapy with 90 Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial. <i>Lancet Haematology</i> , 2017, 4, e35-e45.	4.6	33
2	Long-term efficacy of anti-PD1 therapy in Hodgkin lymphoma with and without allogenic stem cell transplantation. <i>European Journal of Cancer</i> , 2019, 115, 47-56.	2.8	33
3	Sequential combination of gemcitabine, vinorelbine, pegylated liposomal doxorubicin and brentuximab as a bridge regimen to transplant in relapsed or refractory Hodgkin lymphoma. <i>Haematologica</i> , 2015, 100, e269-e271.	3.5	24
4	In Situ Hepatitis C NS3 Protein Detection Is Associated with High Grade Features in Hepatitis C-Associated B-Cell Non-Hodgkin Lymphomas. <i>PLoS ONE</i> , 2016, 11, e0156384.	2.5	19
5	Transmission of Hepatitis E Virus With Plasma Exchange in Kidney Transplant Recipients. <i>Transplantation</i> , 2018, 102, 1351-1357.	1.0	14
6	Primary bone diffuse large B-cell lymphoma: a retrospective evaluation on 76 cases from French institutional and LYSA studies. <i>Leukemia and Lymphoma</i> , 2016, 57, 2820-2826.	1.3	13
7	Outcomes of refractory or relapsed Hodgkin lymphoma patients with post-autologous stem cell transplantation brentuximab vedotin maintenance: a French multicenter observational cohort study. <i>Haematologica</i> , 2022, 107, 1681-1686.	3.5	12
8	Tandem haematopoietic stem cell transplantation for High Risk relapsed/refractory Hodgkin Lymphoma: a LYSA study. <i>British Journal of Haematology</i> , 2018, 181, 341-349.	2.5	10
9	The role of radiotherapy as salvage and/or consolidation treatment in relapsed/refractory and high-risk diffuse large B-cell lymphoma. <i>European Journal of Haematology</i> , 2018, 101, 150-159.	2.2	6
10	Impact of genotype in relapsed and refractory acute myeloid leukaemia patients treated with clofarabine and cytarabine: a retrospective study. <i>British Journal of Haematology</i> , 2019, 187, 65-72.	2.5	3
11	Amahrelis : Adcetris Maintenance after Autologous Stem Cell Transplantation in Hodgkin Lymphoma : A Real Life Study from Sfgmtc and Lysa Groups. <i>Blood</i> , 2020, 136, 20-21.	1.4	3
12	Can nivolumab alone cure patients with relapse or refractory Hodgkin lymphoma? A 5-year analysis of the French early access program (EPA). <i>British Journal of Haematology</i> , 2022, , .	2.5	3
13	The Combination of High Expression of CD68-Positive Tumor-Associated Macrophages and PET2-Positivity Predicts Unfavorable Outcome in Patients with Classical Hodgkin Lymphoma Treated in the Lysa AHL2011 Study. <i>Blood</i> , 2016, 128, 1825-1825.	1.4	1
14	Clonal B-Cell Lymphocytosis with Marginal Zone Features and Splenic Marginal Zone Lymphoma Share a Similar Cytogenetic and Mutational Profile. <i>Blood</i> , 2016, 128, 2962-2962.	1.4	0